

BD launches infectious disease molecular Dx platform

May 23, 2022—BD announced the U.S. launch of its fully automated, high-throughput infectious disease molecular diagnostics platform, the BD COR MX. The 510(k)-cleared instrument is an analytic option for the modular and scalable BD COR system.

The first test available on the BD COR MX is the BD CTGCTV2 molecular assay, a single test that detects three nonviral sexually transmitted infections—*Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis*. Collection options for the assay include self-collection in a clinical setting, vaginal/endocervical swab, urine, and liquid-based cytology. Additional assays for the MX instrument are in development.